MUC16 and prostate cancer: Proteomic biomarkers possess potential applications in diverse healthcare areas, encompassing disease diagnosis, prognosis, disease progression monitoring, and prediction of treatment response.[101] For instance, in clinical settings, prostate‐specific antigen (PSA) serves as a biomarker for prostate cancer, while cancer antigen 125 (CA‐125) is utilized as a biomarker for ovarian cancer.